Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 7/20 | 0.38 |
| ▸ | CCND1 | P24385 | 7/20 | 0.38 |
| ▸ | CCNE2 | O96020 | 5/20 | 0.38 |
| ▸ | CCNE1 | P24864 | 5/20 | 0.38 |
| ▸ | CDK2 | P24941 | 5/20 | 0.38 |
| ▸ | PRKACA | P17612 | 2/20 | 0.35 |
| ▸ | PRKACG | P22612 | 2/20 | 0.35 |
| ▸ | PRKACB | P22694 | 2/20 | 0.35 |
| ▸ | PRKCI | P41743 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.32 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.31 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18876204 | 0.83 | CDK4 (0.36) | CDK4CCND1CCNE2CCNE1CDK2 | |
| SCHEMBL15450901 | 0.78 | KDM4E (0.33) | CDK4CCND1CCNE2CCNE1CDK2 | |
| SCHEMBL12536131 | 0.78 | CDK4 (0.39) | CDK4CCND1CCNE2CCNE1CDK2 | |
| SCHEMBL24901130 | 0.77 | HTR2A (0.33) | — | |
| SCHEMBL15374081 | 0.75 | CDK4 (0.37) | CDK4CCND1CCNE2CCNE1CDK2 | |
| SCHEMBL18876149 | 0.74 | CDK4 (0.36) | CDK4CCND1CCNE2CCNE1CDK2 | |
| SCHEMBL18014684 | 0.73 | KDM4E (0.38) | CDK4CCND1CCNE2CCNE1CDK2 | |
| SCHEMBL21936201 | 0.73 | KDM1A (0.32) | — | |
| SCHEMBL21135077 | 0.73 | PTGS2 (0.34) | CDK4CCND1CCNE2CCNE1CDK2 | |
| SCHEMBL16982968 | 0.72 | CYP2A6 (0.40) | CDK4CCND1CCNE2CCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11193065-B2 | Liquid crystal composition, method of producing the same, and retardation film constituted from the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2021-12-07 | — | — | US | disclosed |
| US-20200165519-A1 | POLYMERIZABLE LIQUID CRYSTAL COMPOSITION AND RETARDATION PLATE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2020-05-28 | — | — | US | disclosed |
| US-20190276744-A1 | LIQUID CRYSTAL COMPOSITION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2019-09-12 | — | — | US | disclosed |
| US-10407619-B2 | Liquid crystal composition | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2019-09-10 | — | — | US | disclosed |
| US-10336938-B2 | Liquid crystal composition | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2019-07-02 | — | — | US | disclosed |
| US-20170335191-A1 | LIQUID CRYSTAL COMPOSITION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-11-23 | — | — | US | disclosed |
| US-20170335191-A1 | LIQUID CRYSTAL COMPOSITION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-11-23 | — | — | US | disclosed |
| US-20170306234-A1 | LIQUID CRYSTAL COMPOSITION, METHOD OF PRODUCING THE SAME, AND RETARDATION FILM CONSTITUTED FROM THE SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-10-26 | — | — | US | disclosed |
| US-20170306234-A1 | LIQUID CRYSTAL COMPOSITION, METHOD OF PRODUCING THE SAME, AND RETARDATION FILM CONSTITUTED FROM THE SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-10-26 | — | — | US | disclosed |
| US-20170283700-A1 | LIQUID CRYSTAL COMPOSITION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-10-05 | — | — | US | disclosed |
| US-20170283700-A1 | LIQUID CRYSTAL COMPOSITION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-10-05 | — | — | US | disclosed |
| US-20170145312-A1 | LIQUID CRYSTAL COMPOSITION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-05-25 | — | — | US | disclosed |
| US-20170145312-A1 | LIQUID CRYSTAL COMPOSITION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170335191-A1 | LIQUID CRYSTAL COMPOSITION | RCC1, CCDC47, ACIN1 | CDK4 1725/4885CCND1 565/4885CCNE2 980/4885 |
| US-10407619-B2 | Liquid crystal composition | RCC1, CCDC47, ACIN1 | CDK4 1725/4885CCND1 565/4885CCNE2 980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.